KalVista Pharmaceuticals, Inc.
KALV
$27.00
$0.010.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 07/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 9.43% | -2.82% | -29.20% | -40.81% | -43.86% |
| Gross Profit | 278.88% | 478.64% | 102.50% | 46.17% | 43.86% |
| SG&A Expenses | 37.32% | 99.05% | 87.57% | 153.87% | 53.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.37% | 69.17% | 37.40% | 36.68% | 2.59% |
| Operating Income | 52.84% | 70.39% | -5.91% | -33.46% | -2.59% |
| Income Before Tax | 50.65% | 71.83% | -21.09% | -43.26% | -6.58% |
| Income Tax Expenses | -- | -267.14% | -- | -- | -- |
| Earnings from Continuing Operations | 54.69% | 88.93% | -26.60% | -48.59% | -16.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.69% | 88.93% | -26.60% | -48.59% | -16.10% |
| EBIT | 52.84% | 70.39% | -5.91% | -33.46% | -2.59% |
| EBITDA | 53.32% | 71.60% | -5.78% | -33.57% | -2.53% |
| EPS Basic | 55.95% | 89.44% | -9.46% | -28.42% | 4.64% |
| Normalized Basic EPS | 52.30% | 74.35% | -4.91% | -24.10% | 12.36% |
| EPS Diluted | 55.95% | 89.44% | -9.46% | -28.42% | 4.64% |
| Normalized Diluted EPS | 52.30% | 74.35% | -4.91% | -24.10% | 12.36% |
| Average Basic Shares Outstanding | 2.86% | 4.84% | 15.65% | 15.71% | 21.74% |
| Average Diluted Shares Outstanding | 2.86% | 4.84% | 15.65% | 15.71% | 21.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |